The collaboration is in line with Orexo’s strategy to broaden the use of its powder-based drug delivery technology AmorphOX®. Abera is a developer of mucosal vaccines and has several preclinical vaccine candidates based on Abera’s innovative vaccine platform. The AmorphOX technology has…